Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heuser

Showing results (131-140 of 280) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemiaFelicitas Thol, Frederik Damm, Andrea Lüdeking, et al.
Cancers|September 30, 2020
Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid LeukemiaSagarajit Mohanty, Nidhi Jyotsana, Amit Sharma, et al.
Haematologica|June 8, 2014
Genetic characterization of acquired aplastic anemia by targeted sequencingMichael Heuser, Carola Schlarmann, Vera Dobbernack, et al.
Leukemia|April 6, 2023
In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blastsGabriele Greve, Geoffroy Andrieux, Pascal Schlosser, et al.
Cancers|August 12, 2023
MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AMLKatrin Teich, Michael Stadler, Razif Gabdoulline, et al.
Haematologica|April 4, 2020
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemiaAnuhar Chaturvedi, Charu Gupta, Razif Gabdoulline, et al.
Hemasphere|April 27, 2023
Palbociclib in Acute Leukemias With <i>KMT2A</i>-rearrangement: Results of AMLSG 23-14 TrialVerena I Gaidzik, Peter Paschka, Richard F Schlenk, et al.
Leukemia|October 6, 2019
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding siteAnuhar Chaturvedi, Ramya Goparaju, Charu Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromesFelicitas Thol, Inna Friesen, Frederik Damm, et al.
Journal of Hematology & Oncology|July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyJorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
Pageof 28

Showing results (131-140 of 280) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemiaFelicitas Thol, Frederik Damm, Andrea Lüdeking, et al.
Cancers|September 30, 2020
Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid LeukemiaSagarajit Mohanty, Nidhi Jyotsana, Amit Sharma, et al.
Haematologica|June 8, 2014
Genetic characterization of acquired aplastic anemia by targeted sequencingMichael Heuser, Carola Schlarmann, Vera Dobbernack, et al.
Leukemia|April 6, 2023
In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blastsGabriele Greve, Geoffroy Andrieux, Pascal Schlosser, et al.
Cancers|August 12, 2023
MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AMLKatrin Teich, Michael Stadler, Razif Gabdoulline, et al.
Haematologica|April 4, 2020
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemiaAnuhar Chaturvedi, Charu Gupta, Razif Gabdoulline, et al.
Hemasphere|April 27, 2023
Palbociclib in Acute Leukemias With <i>KMT2A</i>-rearrangement: Results of AMLSG 23-14 TrialVerena I Gaidzik, Peter Paschka, Richard F Schlenk, et al.
Leukemia|October 6, 2019
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding siteAnuhar Chaturvedi, Ramya Goparaju, Charu Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromesFelicitas Thol, Inna Friesen, Frederik Damm, et al.
Journal of Hematology & Oncology|July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyJorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
Pageof 28